About the Company
We do not have any company description for Eidos Therapeutics Inc at the moment.
Please visit http://eidostx.com for more information about the company.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EIDX News
Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug
The rights were acquired from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Acoramidis is ...
Bayer purchases heart drug for up to $310 million
Bayer said on Monday it acquired the exclusive marketing rights for Europe for a new drug that is under regulatory review to ...
Bayer acquires exclusive marketing rights for acoramidis in Europe from Eidos & BridgeBio
Bayer has acquired the exclusive marketing rights for acoramidis in Europe from Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. Acoramidis is a highly potent and ...
Ovid Therapeutics Inc OVID
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
EFTR eFFECTOR Therapeutics, Inc.
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript
G1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call Transcript February 28, 2024 G1 Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.27.
Kintara Therapeutics Inc KTRA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Bayer purchases heart drug for up to $310 mln
The German drugmaker said it struck the deal with Eidos Therapeutics Inc., BridgeBio International GmbH and BridgeBio Europe B.V. The drug acoramidis is under review to treat a progressive hear ...
Loading the latest forecasts...